All News

Researchers found that some caregivers face racism and discrimination as they care for loved ones with cancer.

Most patients with cancer may not be discussing the cost of care with their clinicians, according to recent research.

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study.

Up to a quarter of patients with breast cancer face financial burden due to the cost of supplements, complimentary therapy and alternative medicines which “may decrease adherence to prescribed medications,” researchers found.

A phase 3 trial found that testosterone recovery after androgen deprivation therapy leads to better quality of life following high-risk prostate cancer.

While translocation renal cell carcinoma tends to respond well to immunotherapy, there is still a need for more investigation into targeted therapies for this patient population.

U.S. Army Reserve Veteran and stage 3 colon cancer survivor discussed the significance of the 2022 passage of the PACT Act and what it means for veterans facing cancer.

My donor is at war.

From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.

It is essential for patients who receive immune checkpoint inhibitors to actively communicate with their care teams when experiencing symptoms, an expert explained.

CURE® highlights some of the most significant lung cancer news of 2023 in honor of Lung Cancer Awareness Month.

An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.

An expert reflects on the recent FDA approval of adjuvant Opdivo for patients with stage 2B or 2C melanoma.

Sometimes after a diagnosis of cancer, plans and attending events can become elusive due to symptoms and treatments.

The Food and Drug Administration revised the existing approval of Keytruda, Herceptin and chemotherapy for patients with unresetable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

Oncology telehealth services became more popular during the COVID-19 pandemic and remain to be important for patients with cancer, according to a recent survey.

This November, our country celebrates 76 years of Veteran’s Day, and we want to increase awareness of veterans with lung cancer in this special issue of CURE.

A cancer community creates support and care throughout a cancer experience.

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.

U.S. veterans face exposures during military service and disparities at home.

Friendship means the world throughout a cancer experience.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia.

This episode of the Cancer Horizons podcast features genitourinary oncologist Ulka Vaishampayan, MBBS, and is sponsored by Bristol Myers Squibb.

Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia.